Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases.
CAR T cell
Cancer targeting
Folate
Folate receptors
Folate transporters
Imaging
Inflammation targeting
One-carbon metabolism
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
12 Mar 2019
12 Mar 2019
Historique:
received:
28
01
2019
accepted:
28
02
2019
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
25
7
2019
Statut:
epublish
Résumé
Folate receptors and transporters and one-carbon metabolism continue to be important areas of study given their essential roles in an assortment of diseases and as targets for treatment of cancer and inflammation. Reflecting this, every 2 years, the Folate Receptor Society organizes an international meeting, alternating between North America and Europe, where basic and translational scientists, clinical oncologists and rheumatologists from both academia and industry convene in an informal setting. The 7th International Symposium on Folate Receptors and Transporters was held in Sant'Alessio Siculo (ME), Taormina, Italy from 1st to 5th of October 2018, organized by Dr. Mariangela Figini from Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. Following the format of previous meetings, more than 50 scientists from 9 different countries attended the 2018 meeting to share ongoing developments, discuss current research challenges and identify new avenues in basic and translational research. An important feature of this meeting was the participation of young investigators and trainees in this area, two (A. Dekhne and N. Verweij) of whom were awarded fellowships to attend this meeting as a recognition of the high scientific quality of their work. This report provides a synopsis of the highlights presented in the following sessions: Barton Kamen Lecture; Targeting one-carbon metabolism in cytosol and mitochondria; Structure and biology of the one-carbon solute transporters; Physiology and pathophysiology of folate receptors and transporters; Folate receptors for targeting tumors and inflammatory diseases; Conventional and new anti-folate drugs for treating inflammatory diseases and cancer; Imaging; Ongoing clinical trials; and Chimeric Antigen Receptor cell therapies of cancer.
Identifiants
pubmed: 30867007
doi: 10.1186/s13046-019-1123-1
pii: 10.1186/s13046-019-1123-1
pmc: PMC6417013
doi:
Substances chimiques
Folic Acid
935E97BOY8
Types de publication
Journal Article
Lecture
Langues
eng
Pagination
125Références
Arthritis Rheum. 2009 Jan;60(1):12-21
pubmed: 19116913
Expert Rev Mol Med. 2009 Jan 28;11:e4
pubmed: 19173758
ACS Nano. 2011 Feb 22;5(2):1109-21
pubmed: 21218823
Eur J Immunol. 2011 Mar;41(3):749-59
pubmed: 21287554
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Inherit Metab Dis. 2012 Jul;35(4):665-70
pubmed: 22108709
Blood. 2012 Jan 19;119(3):696-706
pubmed: 22117050
Eur J Cancer. 2012 Mar;48(4):416-24
pubmed: 22209266
Cell. 2012 Jun 8;149(6):1353-67
pubmed: 22682254
Mol Pharm. 2013 Jan 7;10(1):161-74
pubmed: 23186264
PLoS One. 2013 May 24;8(5):e63705
pubmed: 23717468
Nat Commun. 2013;4:2123
pubmed: 23828504
J Clin Oncol. 2013 Dec 10;31(35):4400-6
pubmed: 24127448
Nat Commun. 2014;5:3128
pubmed: 24451681
ACS Chem Biol. 2014 Apr 18;9(4):1044-51
pubmed: 24527883
J Biol Chem. 2014 May 30;289(22):15507-17
pubmed: 24733394
Cold Spring Harb Perspect Biol. 2014 Jun 02;6(6):null
pubmed: 24890511
Mol Pharm. 2014 Sep 2;11(9):3068-79
pubmed: 25057799
Cancer Discov. 2014 Dec;4(12):1406-17
pubmed: 25186948
Drug Resist Updat. 2014 Oct-Dec;17(4-6):89-95
pubmed: 25457975
Nanoscale. 2015 Feb 14;7(6):2336-51
pubmed: 25504081
Nat Rev Drug Discov. 2015 Mar;14(3):203-19
pubmed: 25698644
Cell Signal. 2015 Jul;27(7):1356-68
pubmed: 25841994
Blood. 2015 May 28;125(22):3466-76
pubmed: 25887778
Mol Cancer Ther. 2015 Jul;14(7):1605-13
pubmed: 25904506
Cell. 2015 Apr 23;161(3):581-594
pubmed: 25910209
Ann Oncol. 2015 Oct;26(10):2034-43
pubmed: 26063635
Mol Cancer Res. 2015 Oct;13(10):1361-6
pubmed: 26101208
Oncotarget. 2015 Oct 6;6(30):28911-28
pubmed: 26359629
Mol Cell Biochem. 2016 Jan;411(1-2):151-60
pubmed: 26433955
Sci Rep. 2015 Oct 13;5:15029
pubmed: 26461067
Oncotarget. 2016 Feb 16;7(7):7368-9
pubmed: 26848977
Leukemia. 2016 Jun;30(6):1355-64
pubmed: 26898190
Cell Metab. 2016 Jun 14;23(6):1140-1153
pubmed: 27211901
Biochemistry. 2016 Aug 16;55(32):4574-82
pubmed: 27439469
Cell Metab. 2017 Jan 10;25(1):27-42
pubmed: 27641100
Neoplasia. 2016 Dec;18(12):775-784
pubmed: 27889646
Mol Cancer Ther. 2017 May;16(5):819-830
pubmed: 28138029
Br J Cancer. 2017 Mar 14;116(6):752-761
pubmed: 28152548
PLoS One. 2017 May 11;12(5):e0177572
pubmed: 28493963
Cancer Res. 2017 Jun 1;77(11):2779-2783
pubmed: 28526770
Mol Pharm. 2017 Nov 6;14(11):3848-3858
pubmed: 28885847
Ann Oncol. 2017 Nov 1;28(11):2725-2732
pubmed: 28945836
Future Oncol. 2018 Jan;14(2):123-136
pubmed: 29098867
Cancer Chemother Pharmacol. 2018 Jan;81(1):1-15
pubmed: 29127457
J Exp Clin Cancer Res. 2018 Feb 6;37(1):20
pubmed: 29409507
J Med Chem. 2018 Mar 8;61(5):2027-2040
pubmed: 29425443
Ann Rheum Dis. 2018 May;77(5):752-759
pubmed: 29431121
Nanomedicine. 2018 Feb 17;14(4):1181-1190
pubmed: 29458213
J Exp Clin Cancer Res. 2018 Feb 26;37(1):29
pubmed: 29478415
Sci Rep. 2018 Jun 12;8(1):8943
pubmed: 29895863
Nanoscale. 2018 Jul 5;10(25):12078-12086
pubmed: 29911715
J Exp Clin Cancer Res. 2018 Jul 21;37(1):163
pubmed: 30031396
Cancer Chemother Pharmacol. 2018 Dec;82(6):987-997
pubmed: 30269276
Drug Deliv Transl Res. 2019 Feb;9(1):366-378
pubmed: 30280318
J Med Chem. 2018 Nov 8;61(21):9637-9646
pubmed: 30296376
PLoS One. 2018 Dec 10;13(12):e0208534
pubmed: 30532219
Science. 1994 Jun 24;264(5167):1948-51
pubmed: 7516582
Cancer Res. 1998 Mar 1;58(5):991-6
pubmed: 9500461
Nature. 1998 Aug 20;394(6695):798-801
pubmed: 9723621